. In association with polyclonal infections, another important issue is hetero-resistance which is defined as the coexistence of susceptible and resistant strains in the same clinical sample 6 . This study was aimed to evaluate the impacts of mixed infections and heteroresistance on treatment of TB patients.
Nowadays, molecular genotyping methods can detect the phenomenon of mixed (polyclonal) infections in tuberculosis (TB). In mixed infections multiple strains of Mycobacterium tuberculosis (M. tuberculosis) are retrieved from an individual patient 1 . Mycobacterial Interspersed Repetitive Unit-Variable Number Tandem Repeat (MIRU-VNTR) genotyping, widely applied in the molecular epidemiology of TB, eases the detection of mixed infections 2 . Based on MIRU-VNTR, mixed infections are defined by the presence of different MIRU-VNTR patterns at two or more loci in the same clinical samples, while clonal heterogeneity is defined as having different patterns at a single locus 3, 4 . There are several studies in which mixed M. tuberculosis infections were evaluated in various geographic areas, but there have been few efforts to examine the impact of this phenomenon on treatment of TB patients 5 . In association with polyclonal infections, another important issue is hetero-resistance which is defined as the coexistence of susceptible and resistant strains in the same clinical sample 6 . This study was aimed to evaluate the impacts of mixed infections and heteroresistance on treatment of TB patients.
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Detection of heteroresistance. A total of 288 colonies (three individual clones for each sample) were analyzed for DST. Among the 66 TB patients, 24.24% (16/66) File 1) . Although there was no significant association between the type of resistance pattern and therapy failure (P > 0.05), there was a strong significant association between heteroresistance and treatment failure (P = 0.0001).
Discussion
Although the existence of mixed M. tuberculosis infections is now generally accepted [7] [8] [9] , comprehensive studies of their impact on treatment are rare. In our study we evaluated this issue among 66 confirmed TB patients. We showed that 53% of the patients showed mixed infection based on direct genotyping of the clinical samples. This demonstrated the high prevalence of polyclonal infection in these TB patients. In comparison with our previous study in which genotyping was performed on cultures, the current study demonstrates that direct genotyping better reveals the polyclonal infection 10 . The strength of direct genotyping was that the results were not limited only to patients with positive smears and cultures.
Polyclonal M. tuberculosis infections may have a negative impact on drug resistance testing performed by both phenotypic (e.g., proportional test) and genotypic methods (e.g., GeneXpert MTB/RIF) 11, 12 . Another problem for diagnosis and treatment of TB patients, which is more difficult to detect by the usual phenotypic DST is hetero-resistance 13 . Accordingly, we decided to perform DST on three single colonies for each clinical sample. Among the 35 patients with mixed infections, 16 (45.71%) showed heteroresistance. Among these 16 patients, six were detected as non-treated patients after six-month follow-up. There was a meaningful association between patients infected with mixed strains, heteroresistance and treatment failure (P < 0.05).
Our results are in agreement with a previous study which have demonstrated that infections with heteroresistance can compromise treatment outcomes 14 . In contrast, Cohen et al. showed that the negative effect of polyclonal infections on the response to early treatment appeared to be independent of a relationship with drug resistance in TB patients in KwaZulu-Natal, South Africa 15 . This difference may be related to the follow-up period; which ended at six and two months in our and Cohen's study, respectively.
There was no significant association between the type of antibiotic resistance pattern and treatment failure in our study. Interestingly, we showed that in one patient among the untreated patients (Patient number 45) with a history of antibiotic therapy, treatment conferred a competitive growth advantage to a multidrug-resistant M. tuberculosis strain. This result is supported by previous reports 16, 17 . Thus, the mixed-infection patients with heteroresistance represents a risk group which may contribute to an increased risk of treatment failure. Therefore, early identification of patients with mixed infections would enable prompt therapy with an optimized drug regimen increasing the cure rate 18 . High resolution whole genome sequencing analysis will elucidate more details in this regard 19 . Mixed-infections in TB can be ruled out only by using molecular techniques (e.g. MIRU-VNTR) of pre-culture sample and analysis of multiple colonies. Prompt detection of polyclonal infections with distinct drug susceptibility patterns will enable suitable drug regimens, which could prevent treatment failure.
We conclude that mixed infections, have a negative impact on treatment of TB patients when co-infecting M. tuberculosis strains display heteroresistance.
Methods
Sample collection. This study was conducted between January 2015 and January 2016. In this period, we received 2850 suspected TB clinical samples. After excluding the non tuberculosis mycobacteria and M. bovis, a total of 66 TB patients were confirmed, who were mainly from Tehran province. Most of the clinical samples in our study were sputa, with one pleural fluid, one axillary abscess and two gastric juice samples. Clinical and demographics data were obtained. All experiments were performed in accordance with guidelines approved by Pasteur Institute International networks. Ethical reviews and informed consent approval were granted by the Ethical Committee of the Pasteur Institute of Iran. Informed consent was obtained from all patients in this study. The results of this research did not influence TB patients' treatment.
Detection of mixed infection. DNA extraction. Genomic DNA was extracted from clinical samples with the Proba-NK DNA extraction kit (DNA-Technology Company, Moscow, Russia) according to the manufacturer's instructions. The DNA was stored at − 20 °C until used for molecular studies.
MIRU-VNTR genotyping.
For screening of mixed infection in our TB patients, MIRU-VNTR was performed on clinical samples which elucidate the polyclonal infection in the whole population of bacteria. Manual MIRU-VNTR genotyping was performed as described by Supply et al. 20 . For each locus, deionized water and DNA from M. tuberculosis H37Rv were used as a negative and positive control, respectively. Amplicons were electrophoretically separated on 1.8% agarose gels, using a 100-bp DNA ladder as size markers. Polyclonal infection was defined to be present if a single sample had more than one amplicon at two or more loci. To avoid laboratory cross contamination, all standard precautions were observed. In addition, absence of amplicon and presence of double alleles were confirmed by three independent round sets of PCRsd.
Culture and DST. Ninety-six clinical specimens from 66 TB patients were processed using standard methods and inoculated in Lowenstein-Jensen (LJ) medium. For all patients DST was done on three single colonies for each clinical sample (Based on the availability of samples, for nine patients three sputa, for twelve patients two sputa and for remaining patients one clinical sample were analyzed). DST was done using the proportion method according to the WHO guidelines based on the following antibiotic concentrations: rifampin (RIF; 40.0 μ g/ml), isoniazid (INH; 0.2 μ g/ml), streptomycin (STR; 4 μ g/ml) and ethambutol (EMB; 2.0 μ g/ml). Bacterial growth on antibiotic-containing media exceeding 1% of the number of colonies on antibiotic-free media were considered to be resistant to the antibiotic. There were two sets of DST readings, the first at 28 days and a further reading after 42 days of incubation.
Patients follow up. Double blind follow up of TB patients was carried out by the physician during the period of six-month treatment (based on WHO recommendation; two months of intensive phase and four months of continuation phase). After this period, the clinical (chest X-ray) and microbiological diagnostic procedures (microscopy and culture of clinical sample) were carried out to evaluate the success or failure of treatment.
Statistical analysis. Multivariable logistic regression was used. All calculations were performed using SPSS version twenty-two (SPSS Inc., Chicago, IL, USA). A p value of < 0.05 was considered significant.
